Clinical trial

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

NCT06905301

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2026-01-23

PhaseN/A

Study timeline

Study start (actual)2026-01-23Date precision: day

Registry last updated2026-05-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

RibociclibDRUG · verified · RxNorm: ribociclib

LetrozoleDRUG · verified · RxNorm: letrozole

AnastrozoleDRUG · verified · RxNorm: anastrozole

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

Saint PetersburgRussia3 MoscowRussia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06905301 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.